Thrivent Financial For Lutherans Akebia Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.92 - $5.06 $337,896 - $585,533	-115,718 Closed	0 $0
Q3 2020 Nov 10, 2020	BUY	$2.39 - $13.08 $141,640 - $775,173	59,264 Added 104.98%	115,718 $290,000
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $231,461 - $578,088	56,454 New	56,454 $428,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $353M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.